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Abstract
While many epidemiological models have being proposed to understand and handle COVID-19, too little
has been invested to understand how the virus replicates in the human body and potential antiviral can be
used to control the replication cycle. In this work, using a control theoretical approach, validated mathemati-
cal models of SARS-CoV-2 in humans are properly characterized. A complete analysis of the main dynamic
characteristic is developed based on the reproduction number. The equilibrium regions of the system are
fully characterized, and the stability of such a regions, formally established. Mathematical analysis high-
lights critical conditions to decrease monotonically SARS-CoV-2 in the host, such conditions are relevant
to tailor future antiviral treatments. Simulation results show the potential benefits of the aforementioned
system characterization.
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1. Introduction
By December 2019, an outbreak of cases of pneumonia of unknown etiology was reported in Wuhan,
Hubei province, China [1]. On January 7, a novel betacoronavirus was identified as the etiological agent
by the Chinese Center of Disease Control and Prevention (CDC), and subsequently named as Severe Acute
Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) [2]. On February 11, the World Health Organization
(WHO) named the disease as Coronavirus disease 2019 (COVID-19) [3]. Although, prevention and control
measures were implemented rapidly, from the early stages in Whuan and other key areas of Hubei [4], the
first reporting of cases outside of China, 2 in Thailand and 1 in Japon [5], showed that the disease was
starting to spread around the world. On March 11, with more that 111.800 cases in 114 countries, and 4921
fatality cases, the COVID-19 is declared pandemic by the WHO [5]. So far, with more than 7.000.000 total
cases confirmed in 213 countries and territories [6, 7], and a estimated case-fatality rate (CFR) of 5.7%
(H1N1 pandemic, CFR<1%)[8], the potential risks associated with this disease are evident.
Facing this situation, and taking into account the nonexistence of vaccines or specific therapeutically
treatments, preventive measures such as social and physical distancing, hand washing, cleaning and dis-
infection of surfaces and use of face masks, among others, have been implemented in order to decrease
the transmission of the virus, which is spread mainly from person-to-person through respiratory droplets
produced when an infected person coughs, sneezes or talks [9]. Furthermore, this infection prevention and
control measures, helps avoid healthcare systems from becoming overwhelmed.
Many epidemiological mathematical models [10, 11, 12] have been proposed to predict the spread of
the disease and evaluate the potential impact of infection prevention and control measures in outbreak
management [13]. However, mathematical models at within-host level that could be useful to understand
SARS-CoV-2 replication cycle and interaction with immune system as well as pharmacological effect of
potential drug therapies [14, 15] are needed. So far, there are approximately 109 trials (including those
not yet recruiting, recruiting, active, or completed) to asses pharmacological therapy for the treatment of
COVID-19 in adult patients[16], including antiviral drugs (i.e. Hydroxychloroquine, Remdesivir, Favipi-
ravir, Lopinavir/Ritonavir, Ribavirin), immunomodulatory agents (i.e. Tocilizumab) and immunoglobulin
therapy, among others.
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Recently, Hernandez-Vargas et. al. [17] proposed different within-host mathematical models (2 based
on target cell-limited model, with and without latent phase, and 1 considering immune response) for 9
infected patients with COVID-19. Numerical results in [17] showed a mean infecting time between suscep-
tible cells of 30 days (about 3 times slower than Ebola and 60 times slower than influenza), which could
explain the slow recuperation rate (12-22 days post symptom onset, pso) showed in COVID-19 infected pa-
tients. Furthermore, they informed within-host reproductive number values consistent to influenza infection
(1.7-5.35).
Although models in [17] have been fitted to COVID-19 patients data, a control theoretical approach
is needed to characterize the model dynamics. Even when the equilibrium states are known, a formal
stability analysis is needed to properly understand the model behavior and, mainly, to properly design
efficient control strategies. Note that the target cell model has been employed previously taking into account
pharmacodynamic (PD) and pharmacokinetics (PK) models of antiviral therapies [18, 19], and this can be
potentially done also for COVID-19.
In this context, the main contribution of this article is twofold. First, a full characterization of equilib-
rium and stability proprieties is performed for the COVID-19 target cell-limited model [17]. Then, formal
properties concerning the state variables behavior before convergence - including an analysis of the virus
peak times - are given. A key aspect in the target cell model for acute infections shows some particularities
such as it has a minimal non-punctual stable equilibrium set, whose stability does not depends on the repro-
duction number. On the other side, assuming a basic reproduction number greater than 1, the virus would
not be cleared before the target cells goes under a given critical value, which is independent of the initial
conditions.
After the introduction given in Section 1 the article is organized as follows. Section 2 presents the
general in-host target cell-limited model used to represent SARS-CoV-2 infection dynamic. Section 3
characterizes the equilibrium sets of the system, and establishes their formal asymptotic stability, by stating
both, the attractivity of the equilibrium set in a given domain, and its ǫ− δ (Lyapunov) local stability. Then,
in Section 4, some dynamical properties of the system are stated, concerning the values of the states at the
infection time t = 0. In Section 5 the general model for the SARS-CoV-2 infection is identified according
to patient data, and the general characteristics of the infection are analyzed. Finally, Section 6 gives the
conclusion of the work, while several mathematical formalism - necessary to support the results of Sections
3 and 4 - are given in Appendices 7, 8 and 9.
1.1. Notation
R and I denote the real and integer numbers, respectively. The real vector space of dimension n is
denoted as Rn. Rn≥0 represents the vectors of dimension n whose components are equal or greater than
zero. The distance from a point x ∈ Rn to a set X ⊂ Rn is defined by ‖x‖X := infz∈X ‖x− z‖2, where
‖ · ‖2 denotes the norm-2. The open ball of radius ǫ around a point x ∈ R
n, with respect to set X , is defined
as Bǫ(x) := {z ∈ X : ‖x − z‖2 < ǫ}. Let us consider the real function y(z) = ze
z , then, the so-called
Lambert function is defined as the inverse of y(·), i.e.,W (z) := f−1(z) in such a way thatW (f(z)) = z.
2. SARS-CoV-2 Within-Host Mathematical Model
Although incomplete by definition, mathematical models of in-host virus dynamic improves the un-
derstanding of the interactions that govern infections and, more important, permits the human intervention
to moderate their effects [20]. Basic in-host infection dynamic models usually include the susceptible
cells, infected cells, and the pathogen particles [21]. Among the most used mathematical models, the tar-
get cell-limited model has been employed to represent and control HIV infection [22, 23, 24], influenza
[25, 26, 27, 18], Ebola [28], dengue [29, 30] among others.
In this work, we consider the mathematical model proposed by Hernandez-Vargas [17] given by the
following set of differential equations (ODEs) :
U˙(t) = −βU(t)V (t), U(0) = U0, (2.1a)
I˙(t) = βU(t)V (t)− δI(t), I(0) = I0 = 0, (2.1b)
V˙ (t) = pI(t)− cV (t), V (0) = V0, (2.1c)
where U [cell], I [cell] and V [copies/mL] represent the susceptible cells, the infected cells, and the virus
load, respectively. The parameter β [(copies/mL)−1day−1] is the infection rate of susceptible cells by the
2
virus. δ [day−1] is the death rate of I . p [(copies/mL)day−1cell−1] is the replication rate of free virus
from infected cell I . c [day−1] is the degradation (or clearance) rate of virus V . The effects of immune
responses are not explicitly described in this model, but they are implicitly included in the death rate of
infected cells (δ) and the clearance rate of virus (c) [26].
The model (2.1) is positive, which means that U(t) ≥ 0, I(t) ≥ 0 and V (t) ≥ 0, for all t ≥ 0. If we
denote x(t) := (U(t), I(t), V (t)), then the states are constrained to belong to:
X := {x ∈ R3≥0}. (2.2)
Another meaningful set is the one consisting in all the states in X with strictly positive amount of virus
and susceptible cells, i.e.,
X := {x ∈ X : U > 0, V > 0}. (2.3)
Note that the set X is an open set.
The initial conditions of (2.1) must be carefully established in order to properly represent the host body
evolution from the beginning of the infection. So, it is assumed that the system is at a healthy steady state
before the infection time t = 0, i.e., V (t) = 0, I(t) = 0, and U(t) = U0, for t < 0. At time t = 0,
a small quantity of virions enters to the host body and, so, a discontinuity occurs in V (t). Indeed, V (t)
jumps from 0 to a small positive value V0 at t0 = 0 (formally, V (t) has a discontinuity of the first kind
at t0, i.e., limt→0− V (t) = 0 while limt→0+ V (t) = V0 > 0. The same scenario arises, for instance,
when an antiviral treatment affects either parameter (say p or β).The jump of p or β can be considered as
a discontinuity of the first kind. In any case, for the time after the discontinuity, the virus may spread or
be cleared in the body, depending on its infection effectiveness. To properly determine what such a spread
means, the following (mathematical) definition is given
Definition 1 (Spreadability of the virus in the host body). Consider system (2.1), constrained by the positive
setX, at some time t0, with U(t0) > 0, I(t0) ≥ 0 and V (t0) > 0 (i.e., x(t0) = (U(t0), I(t0), V (t0)) ∈ X ).
Then, it is said that the virus spreads (in some degree) in the body host for t > t0 if there exists at least one
t∗ > t0 such that V˙ (t
∗) > 0.
The latter definition states that the virus spreads in the body host if V (t) has at least one local maximum.
On the other hand, the virus does not spread if V (t) is strictly decreasing for all t > t0, which means that
V (t) has neither local minima nor local maxima. As it will be stated later on (Property 1), limt→∞ V (t) = 0
for system (2.1), independently of the fact that the virus reaches or not a maximum (this is a key difference
between acute and chronic infection models [20, 21]).
The infection severity could be related with the virus spreadability established in Definition 1. Liu et.al.
[31] have shown that patients with severe COVID-19 tend to have a high viral load and a long virus shedding
period. The mean viral load of severe cases was around 60 times higher than that of mild cases, suggesting
that higher viral loads might be associated with severe clinical outcomes. Furthermore, they found that
the viral load of severe cases remained significantly higher for the first 12 days after the appearance of
the symptoms than those of corresponding mild cases. Mild cases were also found to have an early viral
clearance, with 90% of these patients repeatedly testing negative on reverse transcription polymerase chain
reaction (RT-PCR) by day 10 post symptoms onset (pso). By contrast, all severe cases still tested positive at
or beyond day 10 pso. In addition, Zheng et.al. [32] from an study with 96 SARS-CoV-2 positive patients
(22 with mild disease and 74 with severe disease) reported a longer duration of SARS-CoV-2 in lower
respiratory samples of severe patients, such as, for patients with severe disease (21 days, 14-30 days) was
significantly longer than in patients with mild disease (14 days, 10-21 days; p=0.04). Moreover, higher viral
loads were detected in respiratory samples, although no differences were found in stool and serum samples.
Although, these findings suggest that reducing the viral load through clinical means and strengthening
management should help to prevent the spread of the virus, they are preliminary and it remains controversial
whether virus persistence is necessary to drive the dysfunctional immune response characteristic of COVID-
19 patients [33].
Remark 1. Note that the virus spreadability may or may not cause a severe infection (a disease that
eventually cause the host death) depending on how much time the virus is above a given value.
To properly establish conditions under which the virus does not spread for t > 0 (i.e., after the infection
time t = 0) the so-called basic reproduction number within-host is defined next.
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Definition 2. The basic reproduction number within-host R is defined as the number of infected cells (or
virus particles) that are produced by one infected cell (or virus particle), at a given time. Its mathematical
expression is given by:
R(t) := U(t)
βp
cδ
. (2.4)
Particularly, for t = 0, this number describes the number of infected cells produced by one infected cell,
when a small amount of virus, V0, is introduced into a healthy stationary population of uninfected target
cells, U0,
R0 := U0
βp
cδ
. (2.5)
A discussion about the way this value is obtained is given in Appendix 8. The relation between the basic
reproduction number at the infection time (R0) and the virus spreadiblity is stated in the next theorem.
Theorem 2.1. Consider system (2.1), constrained by the positive set X, at the beginning of the infection,
i.e., U(0) = U0 > 0, I(0) = 0 and V (0) = V0 > 0 (i.e., x(0) = (U(0), I(0), V (0)) ∈ X ). Then, a
sufficient condition (not necessary) for the virus not to spread in the host body is given by R0 < 1.
Proof: It is easy to see that the initial conditions are such that RV (0) :=
pI(0)
cV (0) = 0 < 1. So, considering
thatR0 < 1 by hypothesis, the result corresponds to Theorem 9.1. (i)., when t0 = 0. 
Remark 2. According to Theorem 9.1, in Appendix 9, there exists a positive value α(0) > 0 (which is an
implicit function of the initial conditions and the parameters, and it can be computed numerically) such
that conditionR0 < 1 + α(0) is a necessary and sufficient condition for the virus not to spread in the host
body, after the infection time t = 0. This means that for R0 > 1 + α(0) the virus spreads in the host, as
it is usually the case in real infections. In any case, the value of α(0) is generally close to zero (when β is
small), so to consider 1 as a threshold for the virus to spread seems to be a reasonable approximation.
Before proceeding with a full dynamic analysis of system (2.1), let us define first the so-called critical
value of the susceptible cells, which shows to be an useful threshold value to properly understand the spread
of the virus.
Definition 3. The critical value for U , Uc, is defined as
Uc :=
cδ
pβ
, (2.6)
which, for fixed system parameters β, p, δ and c, is a constant.
Note that U(t) < Uc if and only ifR(t) < 1, for every t ≥ 0.
2.1. Equilibrium set characterization
By equaling U˙ , I˙ and V˙ to zero, in (2.1), it can be shown that the system only has healthy equilibria of
the form xs = (Us, 0, 0), with Us being an arbitrary positive value, i.e., Us ∈ [0,∞). Thus, there is only
one equilibrium set, which is the healthy one, and it is defined by
Xs := {(U, I, V ) ∈ R
3 : U ∈ [0,∞), I = 0, V = 0}. (2.7)
To have a first look on the stability of the equilibrium points in Xs, system (2.1) can be linearized at a
general state xs ∈ Xs. By simplifying (2.1) we have:
U˙ = f(U, I, V ),
I˙ = g(U, I, V ),
V˙ = h(U, I, V ).
Then, the Jacobian matrix is given by
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J =


∂f
∂U
∂f
∂I
∂f
∂V
∂g
∂U
∂g
∂I
∂g
∂V
∂h
∂U
∂h
∂I
∂h
∂V

 =

 −βV 0 −βUβV −δ βU
0 p −c

 .
And the Jacobian evaluated at any point xs ∈ Xs reads
As =

 0 0 −βUs0 −δ βUs
0 p −c

 .
with Us ∈ [0,∞). Then, the eigenvalues (λ1, λ2, λ3) are computed as the solution to Det(As − λI) = 0,
being the matrix As − λI given by
As − λI =

 −λ 0 −βUs0 (−δ − λ) βUs
0 p (−c− λ)

 .
Then, considering thatDet(A− λI) = λ[−λ2 − (c+ δ)λ+ (βUsp− cδ)], conditionDet(A− λI) = 0 is
given by
λ[−λ2 − (c+ δ)λ+ (βUsp− cδ)] = 0.
The first eigenvalue is trivially given by λ1 = 0. The other two, are given by:
λ2,3 =
(c+ δ)±
√
(c+ δ)2 + 4(βUsp− cδ)
−2
.
To analyze the eigenvalues qualitatively, note that for Us = Uc it is
λ2,3 =
(c+ δ)±
√
(c+ δ)2 + 4(βp cδ
pβ
− cδ)
−2
=
(c+ δ)±
√
(c+ δ)2 + 4(cδ − cδ)
−2
=
(c+ δ)± (c+ δ)
−2
,
which means that λ2 = 0 and λ3 = −(c+δ) < 0 (given that c, δ > 0). Furthermore, λ2 < 0 and λ3 < 0 for
Us < Uc; and λ2 > 0 and λ3 < 0 for Us > Uc. Given that the maximum eigenvalue is the one dominating
the stability behavior of the equilibrium under consideration, it is possible to infer how the system behaves
near some segments of Xs. The first intuition is that the equilibrium set
X 1s := {(U, I, V ) ∈ R
3 : U ∈ [0,Uc), I = 0, V = 0} (2.8)
is stable, and that the equilibrium set
X 2s := {(U, I, V ) ∈ R
3 : U ∈ [Uc,∞), I = 0, V = 0} (2.9)
is unstable. These are just intuitions, given that one of the eigenvalues of the linearization system is null and
so the linear approximation cannot be used to fully determine the stability of the nonlinear system (Theorem
of Hartman-Grobman [34, 35]). To formally prove the asymptotic stability of X 1s in a given domain, it is
necessary to prove its global attractivity (in such domain) and local ǫ-δ stability.
3. Asymptotic stability of the equilibrium sets
A key point to analyze the general asymptotic stability (AS) of system (2.1) is to consider stability of
the complete equilibrium sets X 1s andX
2
s , and not of the single points inside them (as defined in Definitions
5, 6 and 7, in Appendix 7). As it is shown in the next subsections, there is no single AS equilibrium points
in this system, although there is an AS equilibrium set (i.e., X 1s ).
As stated in Definition 7, in Appendix 7, the AS of X 1s requires both, attractivity and ǫ − δ stability,
which are stated in the next two subsections, respectively. Then, in Subsection 3.3 the AS theorem is
formally stated.
5
3.1. Attractivity of set X 1s in X
Before proceeding with the formal theorems of the atractivity of X 1s , let us consider the following key
property of system (2.1) concerning the atractivity of Xs.
Property 1 (Atractivity of Xs). Consider system (2.1) constrained by the positive set X, at some arbitrary
time t0, with U(t0) > 0, I(t0) ≥ 0 and V (t0) > 0 (i.e., x(t0) = (U(t0), I(t0), V (t0)) ∈ X ). Then,
U∞ := limt→∞ U(t) is a constant value smaller than U(t0), I∞ := limt→∞ I(t) = 0 and V∞ :=
limt→∞ V (t) = 0, which means that x(t) = (U(t), I(t), V (t)) tends to some state in Xs.
Proof: Since U˙(t) ≤ 0 for all t ≥ 0 and all (U(t0), I(t0), V (t0)) ∈ X , by (2.1a) U(t) is a decreasing
function (no oscillation can occur). Since U(t0) > 0 and V (t0) > 0, then U∞ = limt→∞ U(t) is a constant
value in [0, U(t0)). Given that U(t) converges to a finite fixed value, then U˙(t) = 0 as t → ∞, by (2.1a).
This implies, by the same equation (2.1a), that U(t)V (t) = 0 as t→∞, and so, from equation (2.1b), that
I˙(t) = −δI(t) as t → ∞, whose solution asymptotically goes to zero. Then, I∞ = limt→∞ I(t) = 0.
Finally, by equation (2.1c)), V˙ (t) = −δV (t) as t→∞, whose solution asymptotically goes to zero. Then
V∞ = limt→∞ V (t) = 0, which completes the proof. 
Property 1 states that Xs is an attractive set for system (2.1), in X , but not the smallest attractive set.
Now, conditions are given to show that the smallest attractive set is given by X 1s .
Theorem 3.1 (Atractivity of X 1s ). Consider system (2.1) constrained by the positive set X. Then, the set
X 1s defined in (2.8) is the smallest attractive set in X . Furthermore, X
2
s , defined in (2.9), is not attractive.
Proof: The proof is divided into two parts. First it is proved that X 1s is an attractive set, and then, that it is
the smallest one.
Attractivity of X 1s : The attractivity of Xs in X is already proved in Property 1. So, to prove the attrac-
tivity of X 1s in X (and to show that X
2
s is not attractive) it remains to demostrate that U∞ ∈ [0,Uc). From
system (2.1), by replacing (2.1a) in (2.1b), it follows that I˙(t) = βU(t)V (t) − δI(t) = −U˙(t) − δI(t),
which implies that
I(t) = (−
1
δ
)(I˙(t) + U˙(t)). (3.1)
From (2.1c) it follows that
V (t) =
1
c
(pI(t)− V˙ (t)). (3.2)
Then, replacing (3.1) in (3.2), we have
V (t) = [p(−
1
δ
)(I˙(t) + U˙(t))− V˙ (t)]
1
c
. (3.3)
Finally, by substituting (3.3) in (2.1a), and multiplying by 1/U(t) both sides of the equation (without loss
of generality we assume that U(t) 6= 0), it follows that
1
U(t)
U˙(t) =
βp
cδ
U˙(t) +
βp
cδ
I˙(t) +
β
c
V˙ (t). (3.4)
This latter equation can be integrated, for general initial conditions U0, I0 and V0, as follows:
ln(
U(t)
U0
) =
βp
cδ
(U(t)− U0) +
βp
cδ
(I(t) − I0) +
β
c
(V (t)− V0). (3.5)
Now, by defining U∞ := limt→∞ U(t), I∞ := limt→∞ I(t), V∞ := limt→∞ V (t), and recalling from
Property 1 that I∞ = V∞ = 0, the latter equation for t→∞, reads
ln(
U∞
U0
) =
βp
cδ
(U∞ − U0) +
βp
cδ
(I∞ − I0) +
β
c
(V∞ − V0)
=
βp
cδ
U∞ −R0 −
βp
cδ
I0 −
β
c
V0
6
=
βp
cδ
U∞ −R0 +K0, (3.6)
whereR0 :=
βp
cδ
U0 (as it was defined in (2.5)) and
K0 := −
β
c
(
p
δ
I0 + V0). (3.7)
Note thatR0 is a function of U0 while K0 is a function of I0 and V0, and, furthermore,R0 > 0 andK0 < 0
for every x0 = (U0, I0, V0) ∈ X . Then, after some manipulation, (3.6) reads
−
βp
cδ
U∞e
−
βp
cδ
U∞ = −
βp
cδ
U0e
−R0eK0 = −R0e
−R0eK0 . (3.8)
Now, by denoting z = z(R0,K0) := −R0e
−R0eK0 and y := −βp
cδ
U∞, the latter equation can be written
as
W (z) = y, (3.9)
or, the same,
W (−R0e
−R0eK0) = −
βp
cδ
U∞, (3.10)
whereW (·) is a Lambert function. Figure 1 shows the graph of such a function, where it can be seen that
it has two branches, denoted as Wp and Wm. However, W (·) = Wp(·) in this case, since Wm → −∞
for z → 0−, which has not biological sense (note that U∞ is a finite value in [0, U0)). Besides, function
−1/e < z(R0,K0) ≤ 0 forR0 > 0 and K0 < 0 (Figure 2 shows a plot of function z(R0,K0) for negative
values of K0 and positive values ofR0), and functionWp maps (−1/e, 0] into (−1, 0], which implies that
1 > −W (z(R0,K0)) ≥ 0, (3.11)
forR0 > 0 and K0 < 0. This way, by (3.10), it follows that
U∞ = −
cδ
βp
W (−R0e
−R0eK0)
= −UcW (−R0e
−R0eK0)
∈ [0,Uc), (3.12)
which completes the proof.
X 1s is the smallest attractive set: It is clear, from the previous analysis, that any initial state x0 =
(U0, I0, V0) in X converges to a state x∞ = (U∞, 0, 0) with U∞ ∈ [0,Uc). This means that every state
xs ∈ X
2
s is not attractive in X and so, neither the whole set X
2
s . Let us consider now a state xs ∈
X 1s and an arbitrary small ball of radius ǫ > 0, w.r.t. X , around it, Bǫ(xs) ∈ X . Take two arbitrary
initial states x0,1 = (U0,1, I0,1, V0,1) and x0,2 = (U0,2, I0,2, V0,2) in Bǫ(xs), such that U0,1 6= U0,2 and
V0,1 6= V0,2. These two states converge, according to equation (3.11), to x∞,1 = (U∞,1, 0, 0) and x∞,2 =
(U∞,2, 0, 0), respectively. Given that function z(R,K) is monotone (injective) in R0 (and so in U0) and
W (z) is monotone (injective) in z, then U∞,1 6= U∞,2. This means that, although both initial states
converge to some state in X 1s , they necessarily converge to different points. Therefore neither single states
xs ∈ X
1
s nor subsets of X
1
s are attractive in X . So, X
1
s is the smallest attractive set and the proof is
concluded. 
Remark 3. Note that X 1s and X
2
s are in the closure of the open set X , which is not in X . In other words,
what Theorem 3.1 shows is that any initial state in X converges to a point onto the boundary of X that does
not belong to X . Furthermore note that, an initial state of the form (U0, 0, 0), U0 > Uc, (i.e., a state in
X 2s ) cannot be attracted by any set since it is - by definition - an equilibrium state (every state in X
2
s will
remains unmodified). This is the reason why it is not possible to consider the attractivity of X 2s in X .
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Figure 1: Lambert function. W (z) has two branches, denoted as Wp (in blue) and Wm (in red). Both branches are
defined for z ∈ [−1/e, 0]: however limz→0−Wp = 0 while limx→0−Wm = −∞, which means that only the branch
Wp will be used in our analysis, as it is shown in the proof.
Figure 2: Function z(R0,K0), forR0 ≥ 0 and K0 ≤ 0.
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Figure 3: Every point in X 1s is ǫ− δ stable but not attractive. Initial states x0 starting arbitrarily close to xs remains (for
all t ≥ 0) arbitrarily close to xs, but does not converges to xs. As a consequence, set X
1
s is AS but the points inside it
are not.
3.2. Local ǫ− δ stability of X 1s
The next theorem states the formal Lyapunov (or ǫ− δ) stability of the equilibrium set X 1s .
Theorem 3.2. Consider system (2.1) constrained by the positive setX. Then, the equilibrium setX 1s defined
in (2.8) is locally ǫ− δ stable.
Proof: Let us consider a particular equilbrium point xs := (Us, 0, 0), with Us ∈ [0,Uc) (i.e., xs ∈ X
1
s ).
Then a Lyapunov function candidate is given by (similar to one used in [36] for chronic infections)
J(x) := U − Us − Us ln(
U
Us
) + I +
δ
p
V. (3.13)
This function is continuous in X, is positive for all nonegative x 6= xs and J(xs) = 0. Function J evaluated
at the solutions of system (2.1) reads:
J˙(x(t)) =
∂J
∂x
x˙(t) =
[
dJ
dU
dJ
dI
dJ
dV
] −βU(t)V (t)βU(t)V (t)− δI(t)
pI(t)− cV (t)


=
[
(1−
Us
U(t)
) 1
δ
p
] −βU(t)V (t)βU(t)V (t)− δI(t)
pI(t)− cV (t)


= (−βU(t)V (t) + UsβV (t)) + (βU(t)V (t)− δI(t)) + (δI(t)−
δc
p
V (t))
= UsβV (t)−
δc
p
V (t) = V (t)(Usβ −
δc
p
). (3.14)
Now, given Us ∈ [0,Uc), with Uc =
δc
βp
, it follows that J˙(x(t)) ≤ 0 for every x ∈ X (note that it is not
true that J˙(x(t)) < 0 for x 6= xs, as shown next, in Remark 4). Then, J is a Lyapunov function for system
(2.1), which means that each xs ∈ X
1
s is ǫ − δ stable. Therefore, it is easy to see that the equilibrium set
X 1s as a whole is also ǫ− δ stable, which completes the proof. 
Remark 4. Note that, in the latter proof, it is not true that J˙(x(t)) < 0 for every nonegative x 6= xs. If for
instance, the function J˙(x(t)) is evaluated at xˆs = (Uˆ , 0, 0), with Uˆ /∈ Us, we have that J˙(xˆs(t)) = 0. In
fact, J˙(x(t)) is null along the whole U axis, given that this axis is an equilibrium set. This means that the
(individual) states in X 1s are ǫ − δ stable, but not attractive.
A schematic plot of such a behavior can be seen in Figure 3.
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Remark 5. A similar behavior can be seen in system x˙ = Ax, when A = [0 − 1; 0 − 1 ], or the 2-state
Kermack-McKendrick epidemic model [37, 38]: S˙ = βSI , I˙ = βSI − δI , being S the susceptible and I
the infected individual. In this latter model,R0 := (δ/β)S0 and (the critical value for S is) Sc = δ/β. The
AS set is given by all the states of the form xs := (Ss, 0), with Ss ∈ [0, Sc). Furthermore, for this system,
the maximum of I occurs when S = Sc.
3.3. Asymptotic stability of X 1s
In the next Theorem, based on the previous results concerning the attractivity and ǫ− δ stability of X 1s ,
the asymptotic stability is formally stated.
Theorem 3.3. Consider system (2.1) constrained by the positive set X. Then, the set X 1s defined in (2.8) is
smallest asymptotically stable (AS) equilibrium set, with a domain of attraction given by X .
Proof: The proof follows from Theorems 3.1, which states that X 1s is the smallest attractive in X , and 3.2,
which states the local ǫ− δ stability of X 1s . 
A critical consequence of the latter Theorem is that no equilibrium point in Xs (neither in X
1
s , nor
in X 2s ) can be used as setpoint in a control strategy design. The effect of antivirals (pharmocodynamic),
for instance, is just to reduce the virus infectivity (by reducing the infection rate β) or the production of
infectious virions (by reducing the replication rate p) [20]. So, the previous stability analysis is still valid
for controlled system, since only a modification of some of the parameters defining Uc is done. In such a
context, only a controller able to consider the whole set X 1s as a target (a set-based control strategy, as zone
MPC [39, 40]) will be fully successful in controlling system (2.1).
4. Characterization for different initial conditions
In this section some further properties of system (2.1) concerning its dynamic are stated, based on the
initial conditions at the infection time t = 0. The objective is to fully characterize the states behavior in
a qualitative way, including the times at which the virus and the infected cells reach their peaks. First,
Property 2 states some characteristics of U∞ for different initial conditions. Then, Theorem 4.1 states a
general relationship between the peak times of V and I and the time at which U reaches its critical value
Uc.
Property 2. Consider system (2.1), constrained by the positive set X, at the beginning of the infection, i.e.,
U(0) = U0 > 0, I(0) = 0 and V (0) = V0 > 0 (i.e., x(0) = (U(0), I(0), V (0)) ∈ X ). Consider also that
V0 is small enough. Then,
i. U∞ → 0 when U0 →∞ or U0 → 0.
ii. U∞ → Uc when U0 → Uc.
iii. 0 < U∞(U0,1, I0, V0) < U∞(U0,2, I0, V0) < Uc, for initial conditions U0,1 < U0,2 < Uc.
iv. 0 < U∞(U0,2, I0, V0) < U∞(U0,1, I0, V0) < Uc, for initial conditions Uc < U0,1 < U0,2.
Proof: If I0 = 0 and V0 ≈ 0 then K0 ≈ 0. Therefore W (−R0e
K0−R0) ≈ W (−R0e
−R0), and U∞ ≈
−UcW (−R0e
−R0) by (3.10).
i. W (−R0e
−R0) → 0 when −R0e
−R0 → 0, which means that either R0 → 0 or R0 → ∞. This
implies that U0 → 0 or U0 →∞, respectively.
ii. W (−R0e
−R0) → −1 when −R0e
−R0 → −1/e, which is true if R0 → 1 or, the same, when
U0 → Uc.
iii. Function z(R0) = R0e
−R0 is strictly decreasing for R0 ∈ (0, 1) (note that R01 :=
cδU0,1
βp
and
R02 :=
cδU0,2
βp
are in (0, 1), since they are smaller than Uc), while −Wp(·) is strictly decreasing
in (−1/e, 0). So, 0 < −Wp(−R01e
−R01) < −Wp(−R02e
−R02) < 1, which implies that 0 <
U∞(U0,1, I0, V0) < U∞(U0,2, I0, V0) < Uc.
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Figure 4: According to equation (3.10), U∞(U0) is plotted for different values of V0. All parameters are equal to 1 for
simplicity, which means that Uc = 1.
iv. Function z(R0) = R0e
−R0 is strictly increasing for R0 ∈ (1,∞), while −Wp(·) is strictly de-
creasing in (−1/e, 0). So, 0 < −Wp(−R02e
−R02) < −Wp(−R01e
−R01) < 1, which implies that
0<U∞(U0,2, I0, V0) < U∞(U0,1, I0, V0) < Uc. Figure 4 shows U∞ as a function of U0, taking V0 as
a parameter. 
Figure 5 shows a phase portrait of system (2.1), where all parameters are equal to 1 for simplicity, which
means that Uc = 1.
Theorem 4.1 (Virus behavior from the infection time). Consider system (2.1), constrained by the positive
set X, at the beginning of the infection, i.e., U(0) = U0 > 0, I(0) = 0 and V (0) = V0 > 0 (i.e.,
x(0) = (U(0), I(0), V (0)) ∈ X ). If the virus spreads (according to Definition 1), then there exist positive
times tˇV , tˆI , tc and tˆV , such that tˇV < tˆI < tc < tˆV , where tˇV and tˆV are the times at which V (t) reaches
a local minimum and a local maximum, respectively, tˆI is the time at which I(t) reaches a local maximum,
and tc is the time at which U(t) reaches Uc. Furthermore, V˙ (t) < 0 for all t > tˆV .
Proof: If I(0) = 0 thenRV (0) < 1, and Theorem 4.1 is a particular case of Theorem 9.1 (ii).
Next, a Remark concerning a particularity of Theorem 4.1 is introduced, that may help to approximately
determine the global maximum of the virus load.
Remark 6. Consider the hypothesis of Theorem 4.1. Then, it can be shown that for V0 → 0, tˆV → tc
from the right, and tˆI → tc from the left, meaning that the peaks of V and I tends to occurs simultaneously
at time tc. This fact can be seen in Table 2, when data coming from real patients are used to identify the
model.
Amain consequence of Theorem 4.1 and Remark 6 is that it guaranties that the virus will monotonically
go to zero only after U is below Uc. That is, any action devoted to steers V to zero before tc may be
counterproductive, since slowing down V implies to soften the decreasing behavior of U , delaying time
tc, and maintaining V large for a longer time. This critical fact has a direct effect in a potential controlled
system, when parameters p or β are scaled down by antiviral treatments. Assuming thatR0 remains greater
than 1, any attempt to steer V to zero before U has taken values below Uc may be unsuccessful, if U is not
controlled first.
11
0
36
2
2
4
UI
Phase Portrait
V
12
4
00
6
Figure 5: Phase portrait of system (2.1), with unitary parameters. Empty circles represent the initial state, while solid
circles represent final states. Note that only the initial states with U0 > Uc = 1 corresponds to scenarios withR0 > 1.
5. Particularization of the model with patient data
In this section, the parameters of model (2.1) will be associated to data from 9 patients with COVID-19
- labeled as A,B,C,D,E,F,G,H and I - reported in [41]. Here, we consider work in [17], where different
models for in-host SARS-CoV-2 were proposed and identified to fit the virus load data collected in [41].
The initial number of target cells U0 is estimated approximately 10
7 cells [17]. I0 is assumed to be 0
while V0 is determined by interpolation considering an incubation period of 7 days (note, that V0 ranges
from 0.02 to 5.01 copies/mLwhich is below the detectable level of about 100 copies/mL). Moreover, the
onset of the symptoms is assumed to occurs 4 to 7 days after the infection time (day 0, Figure 6 and 7).
Since the viral load is measured in logarithmic scale, the parameter fitting was performed minimizing
the root mean square (RMS) difference on logarithmic scale between the model predictive output (Vˆi) and
the experimental measurements (Vi), employing the Differential Evolution (DE) algorithm proposed in
[17, 20]. The parameters and the initial conditions (U0, I0 and V0, with t0 = 0 the infection time) of each
patient are collected in Table 1.
Table 1: Target limited cell model parameter values for different patients with COVID-19 [17].
Patient β δ p c
A 9.98× 10−8 0.61 9.3 2.3
B 1.77× 10−7 14.11 20.2 0.8
C 8.89× 10−7 79.51 134.4 0.4
D 3.15× 10−8 45.51 620.2 2.0
E 5.61× 10−8 7.51 96.4 5.0
F 1.41× 10−8 37.61 995.0 0.6
G 1.77× 10−8 8.21 338.4 5.0
H 1.58× 10−8 21.11 927.8 1.8
I 4.46× 10−9 4.21 994.6 4.3
According to the system analysis developed in previous sections, some relevant dynamical values are
shown in Table 2. Constant α(0) (defined in Theorem 9.1) is small than 10× 10−4 for all the patients, so it
is not taken into account for the study.
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Table 2: Characterization Parameters of patients with COVID-19.
Patient Uc U∞ R0 K0 tˆI tc tˆV Vmax
A 1.51× 106 1.36× 104 6.61 −2.17× 10−7 10.16 10.24 10.58 1.73× 107
B 3.15× 106 4.88× 105 3.18 −6.87× 10−8 11.54 12.26 12.32 4.35× 106
C 2.66× 105 4.81× 10−10 37.57 −6.89× 10−7 1.43 1.67 1.69 1.47× 107
D 4.65× 106 1.67× 106 2.15 −4.89× 10−9 9.04 9.42 9.44 2.33× 107
E 6.94× 106 4.58× 106 1.44 −3.48× 10−9 15.02 15.16 15.24 4.03× 106
F 1.61× 106 2.03× 104 6.21 −7.28× 10−9 7.12 7.76 7.78 1.42× 108
G 6.84× 106 4.43× 106 1.46 −1.1× 10−9 14.80 14.92 15.00 1.44× 107
H 2.59× 106 2.3× 105 3.86 −2.72× 10−9 5.16 5.44 5.48 1.577× 108
I 4.08× 106 1.14× 106 2.45 −3.21× 10−10 9.28 9.38 9.50 2.60× 108
Figures 6 and 7 shows the evolution of V and U for all patients. As expected, the states converges to
X 1s , although significantly different behavior can be observed for the different patients. From Figure 7 it
can be seen that the healthy cells final value U∞ is reduced in cases of patients with large values of R0,
in spite all patients have the same initial U0. This can be explained from the fact that W (R0e
−R0eK0) is
monotonically decreasing forR0 > 1 (see Figures 1 and 2), and therefore, 0 < U∞(R01) < U∞(R02) for
R01 > R02 > 1. Note that the healthy cells of patient C converges to U∞ equals to 4.810× 10
−10 [cell],
which can be explained by the fact that this patient has a reproduction number (R0) of 37.57, which is
5.2 times above the cohort mean value of 7.21. Figure 6 and Table 2 show that the viral load of patient C
reaches the peak at 1.69 days post infection (dpi) (40.56 hours post infection, hpi).
Furthermore, from Figure 6, it can be seen that for all the cases the viral load spreads (i.e.: the virus
presents a peak) although RV (0) < 0 for all patients (i.e., I0 = 0). This can be justified since U0 ≫ Uc
and, therefore,R0 will be greater than 1 + α(0) for all patients (note that, α(0) < 10× 10
−4). Moreover,
from Table 2, we can corroborate that tˆI > tc > tˆV which is in accordance to what is stated in Theorem
4.1.
Concerning the immune response, this model makes the assumption that it is constant and independent
on viral load as well as infected cells. Furthermore, neither innate or adaptive response are modeled,
being the viral load dynamic mainly limited by target cells availability. Since recent studies have shown a
dysfunctional immune response (i.e.: lymphogenia, desregulated secretion of pro-inflammatory cytokines,
excessive infiltration of monocytes, macrophages and T cells, among others) [33, 42], this effect should
be added in the proposed model, in order to have a more reliable representation (and, eventually, a more
realistic control objective). In addition, a more reliable standard to measure the severity of disease could be
related with the viral spreadability as well as the deregulated inflammatory response.
6. Conclusions
In this work a full dynamical characterization of a COVID-19 in-the-host target-cell model is performed.
Opposite to what happens in other similar models, it is shown that there exists a minimal non-punctual
stable equilbrium set depending only on the system parameters. Furthermore, it is shown that there exists a
parameter-depending threshold for the susceptible cells that fully characterizes the virus and infected cells
qualitative behavior. Simulations performed with real-patient data demonstrate the potential utility of such
system dynamic characterization to tailor the the most valuable pipeline drugs against SARS-CoV-2.
7. Appendix 1. Stability theory
In this section some basic definitions and results are given concerning the asymptotic stability of sets
and Lyapunov theory, in the context of non linear continuous-time systems. All the following definitions
are referred to system
x˙(t) = f(x(t)), x(0) = x0, (7.1)
where x is the system state constrained to be in X ⊆ Rn, f is a Lipschitz continuous nonlinear function,
and φ(t;x) is the solution for time t and initial condition x.
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Figure 6: Virus time evolution for all patients. As it can be seen, very different behaviors are obtained. Vclear denotes a
values of 50 [copies/ml] under which the virus is considered cleared.
Definition 4 (Equilibrium set). Consider system 7.1 constrained by X. The set Xs ⊂ X is an equilibrium
set if each point x ∈ Xs is such that f(x) = 0 (this implying that φ(t;x) = x for all t ≥ 0).
Definition 5 (Attractivity of an equilibrium set). Consider system 7.1 constrained by X. A closed equilib-
rium set Xs ⊂ X is attractive in X ⊂ X if limt→∞ ‖φ(t;x)‖Xs = 0 for all x ∈ X .
Any set containing an attractive set is attractive, so the significant attractive of a constrained system set
is given by the smallest one.
Definition 6 (ǫ − δ local stability of an equilibrium set). Consider system 7.1 constrained by X. A closed
equilibrium set Xs ⊂ X is ǫ − δ locally stable if for all ǫ > 0 it there exists δ > 0 such that in a given
boundary of Xs, ‖x‖Xs < δ, it follows that ‖φ(t;x)‖Xs < ǫ, for all t ≥ 0.
Definition 7 (Asymptotic stability (AS) of an equilibrium set). Consider system 7.1 constrained by X. A
closed equilibrium set Xs ∈ X is asymptotically stable (AS) in X ⊂ X if it is ǫ − δ locally stable and
attractive in X .
Theorem 7.1 (Lyapunov theorem). Consider system 7.1 constrained by X and an equilibrium state xs ∈
Xs ⊂ X. Let consider a function V (x) : R
n → R such that V (x) > 0 for x 6= xs, V (xs) = 0 and
V˙ (x(t)) ≤ 0, denoted as Lyapunov function. Then, the existence of such a function implies that xs ∈ Xs
is ǫ − δ locally stable. If in addition V˙ (x(t)) < 0 for all x 6= xs and V˙ (xs) = 0, then xs ∈ Xs is
asymptotically stable.
8. Appendix 2. Derivation of the basic reproduction numberR0
The derivation of the basic reproduction number R0 will be given by means of the concept of next-
generation matrix [43]. Consider system (2.1) and assume that a healthy equilibrium exists, of the form
x0 = (U0, 0, 0), and it is stable in absence of disease. Of the complete state of system (2.1), x = (U, I, V ),
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Figure 7: Healthy cells time evolution for all patients. Pat C shows a very slow value of U∞ (practically zero), which
suggest that the selected value of U0 = 1.0e
7 is too large.
only two states depend on infected cells, that is I and V . Let us rewrite the ODEs for this two states in the
form
I˙(t) = FI(x) − GI(x)
V˙ (t) = FV (x)− GV (x)
where Fi(x), i = {I, V }, is the rate of appearance of new infections in compartment i, while Gi(x),
i = {I, V }, is the rate of other transitions between compartment i and the other infected compartments,
that is
FI(x) = βU(t)V (t) and GI(x) = δI(t)
FV (x) = 0 and GV (x) = −pI(t) + cV (t)
If we now define
F =


∂FI(x)
∂I
∂FI(x)
∂V
∂FV (x)
∂I
∂FV (x)
∂V


x=x0
=
[
0 βU0
0 0
]
and
G =


∂GI(x)
∂I
∂GI(x)
∂V
∂GV (x)
∂I
∂GV (x)
∂V


x=x0
=
[
δ 0
−p c
]
then matrix FG−1, represents the so-called next-generation matrix. Each (i, j) entry of such a matrix
represents the expected number of secondary infections in compartment i produced by an infected cell
introduced in compartment j. The spectral radius of this matrix, that is, the maximum absolute value of its
eigenvalues, defines the basic reproduction numberR0.
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For the specific case of system (2.1), the next-generation matrix is given by
FG−1 =


βpU0
cδ
βU0
c
0 0


Therefore, the basic reproduction numberR0 is given by
R0 =:
βpU0
cδ
Notice that R0 coincides with the entry (1, 1) of matrix FG
−1, thus meaning that R0 represents the
expected number of secondary infections produced in compartment I by an infected cell originally in I .
9. Appendix 3. General virus characterization for the dynamic (2.1)
The next theorem characterizes all possible virus behavior, depending on the arbitrary initial conditions
and the parameters.
Theorem 9.1 (Virus behavior from an arbitrary time). Consider system (2.1), constrained by the pos-
itive set X, at some arbitrary time t0, with U(t0) > 0, I(t0) ≥ 0 and V (t0) > 0 (i.e., x(t0) =
(U(t0), I(t0), V (t0)) ∈ X ). Let defineR(t) :=
βpU(t)
δc
andRV (t) :=
pI(t)
cV (t) . Then,
i. if RV (t0) < 1 and R(t0) < 1 + α(t0), where α(t0) is a positive value, depending on I(t0), V (t0)
and the parameters, then, V˙ (t) < 0 for all t > t0 (i.e., V (t) is strictly decreasing for all t > t0 and,
so, the virus does not spread in the body host),
ii. if RV (t0) < 1 and the virus spreads in the body host (i.e. V (t) reaches a local maximum, at some
time tˆV > t0, before it goes to zero), thenR(t0) > 1+α(t0). Even more, V (t) has a local minimum
at some time tˇV > t0, with tˇV < tˆV , and after the local maximum it is strictly decreasing, i.e.,
V˙ (t) < 0 for all t > tˆV . On the other hand, I(t) has only one local maximum at time tˆI , being
t0 < tˇV < tˆI < tc < tˆV , where tc is the time whenR reaches 1 from above (or, the same, when U(t)
reaches its critical value Uc).
iii. if RV (t0) > 1, then it there exists tˆV > t0 such that V˙ (t) > 0 for all t0 < t < tˆV , while V˙ (t) < 0
for all t > tˆV (i.e., V (t) has a global maximum at tˆV and then it is strictly decreasing for all t > tˆV ).
This means that the virus spreads in the host body.
Proof: First note that for positive parameters, equation (2.1.a) implies that U˙(t) < 0 for all t ≥ t0 and,
so, R(t) = U(t)βp
cδ
is strictly decreasing for all t ≥ t0. Given that R∞ := limt→∞R(t) = U∞
βp
cδ
and
U∞ < Uc :=
cδ
βp
(see Theorem 3.1), thenR∞ < 1. So, forR(t0) > 1, there exists only one time
tc > t0, (9.1)
at whichR(tc) = 1, beingR(t) > 1 for t0 < t < tc andR(t) < 1 for t > tc.
i. By hypothesis, RV (t0) =
pI(t0)
cV (t0)
< 1, which implies that V˙ (t0) < 0 (V starts decreasing at t0).
On the other hand, by Lemma 1, V reaches a minimum or an inflection point at at time t∗V > t0 if
R(t∗V ) ≥ 1. ButR(t) is strictly decreasing and, so, to reach 1 (at least) at t
∗
V > t0 it must be
R(t0) = 1 + α(t0), (9.2)
for some α(t0) > 0. However, by hypothesis it is R(t0) < 1 + α(t0), which implies that V˙ (t) < 0
for all t > t0. This concludes the proof.
ii. By hypothesis, RV (t0) < 1, which means that V˙ (t0) < 0, and V (t) reaches a local maximum at
some time tˆV > t0. Therefore, V (t) must reach a local minimum at some time t0 < tˇV < tˆV . At
both, the local minimum and maximum it is V˙ (tˇV ) = 0 and V˙ (tˆV ) = 0. Then, by Lemma 1 it is
R(tˇV ) > 1 andR(tˆV ) < 1, respectively.
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Since R(t) is strictly decreasing for t > t0 and tˇV > t0 (note that V˙ (t0) < 0 and V˙ (tˇV ) = 0, so tˇV
cannot be equal to t0.), then R(t0) > R(tˇV ) > 1, which implies that R(t0) > 1 + α(t0) for some
α(t0) > 0. Furthermore, t0 < tˇV < tc < tˆV (R crosses 1 at time tc between tˇV and tˆV ) and, given
thatR(tˆV ) < 1, V cannot reaches another local minimum after its local maximum. This implies that
V˙ (t) < 0 for t > tˆV .
From the minimum andmaximum conditions of V , at times tˇV and tˆV , they are V˙ (tˇV ) = 0, V¨ (tˇV ) >
0 and V˙ (tˆV ) = 0, V¨ (tˆV ) < 0, respectively. After some algebraic computation, it is easy to see that
I˙(tˇV ) > 0 and I˙(tˆV ) < 0, which means that I(t) must reach a maximum at some time tˆI , fulfilling
tˇV < tˆI < tˆV . Even more, it must be I˙(tˆI) = 0, or
βU(tˆI)V (tˆI)− δI(tˆI) = 0. (9.3)
Given that V˙ (t) > 0 for tˇV < t < tˆV (it goes from its minimum to its maximum), then by (2.1.a),
I(tˆI) >
c
p
V (tˆI). Replacing this later condition in (9.3), it follows that
(βU(tˆI)−
δc
p
)V (tˆI) > βU(tˆI)V (tˆI)− δI(tˆI) = 0, (9.4)
which implies that R(tˆI) =
βpU(tˆI )
δc
> 1 and, then, tˆI < tc. Therefore, t0 < tˇV < tˆI < tc < tˆV ,
which concludes the proof.
iii. By hypothesis, RV (t0) =
pI(t0)
cV (t0)
> 1, which implies V˙ (t0) = pI(t0) − cV (t0) > 0 (V starts
increasing at t0). Since V∞ = 0 (Theorem 3.1), then, there exists tˆV > t0 such that V (tˆV ) is a
maximum. According to Lemma 1, if V has a maximum at tˆV , thenR(tˆV ) < 1.
On the other hand, for V (t) to reach a minimum after time tˆV , it must be R(tˆV ) > 1. But R(t) is
strictly decreasing for t > t0, which means that no further minimum exists after tˆV . This implies that
V˙ (t) < 0 for all t > tˆV , which concludes the proof. 
Lemma 1. Consider system (2.1), constrained by the positive setX, at some arbitrary time t0, with U(t0) >
0, I(t0) ≥ 0 and V (t0) > 0 (i.e., x(t0) = (U(t0), I(t0), V (t0)) ∈ X ). Then, (i) if V (t) reaches a local
minimum at time t∗V > t0, then R(t
∗
V ) > 1, (ii) if V (t) reaches a local maximum at time t
∗
V > t0, then
R(t∗V ) < 1, and (iii) if V (t) reaches an inflection point at time t
∗
V > t0 (a point in which V˙ = 0 and
V¨ = 0), then t∗V = tc, where tc is the (unique) time at which R reaches 1 (i.e., R(tc) = 1 or, the same,
U(tc) = Uc).
Proof: Any of the three hypothesis (V (t) reaches a local minimum, a local maximum or a inflection point)
implies that
V˙ (t∗V ) = pI(t
∗
V )− cV (t
∗
V ) = 0, (9.5)
which means that
I(t∗V ) = p/cI(t
∗
V ). (9.6)
Consider the critical case of an inflection point, i.e.,
V¨ (t∗V ) = pI˙(t
∗
V )− cV˙ (t
∗
V ) = pI˙(t
∗
V ) = 0. (9.7)
From (9.7) it is I˙(t∗V ) = 0 which, by (2.1.b) at t
∗
V , is equivalent to
I˙(t∗V ) = βU(t
∗
V )V (t
∗
V )− δI(t
∗
V ) = 0. (9.8)
Now, by (9.6), we have
(
βp
c
U(t∗V )− δ)I(t
∗
V ) = 0. (9.9)
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Given that I(t∗V ) > 0 (note that I(t) is positive for all t > 0), then
βp
c
U(t∗V )− δ = 0, or
R(t∗V ) =
βp
cδ
U(t∗V ) = 1. (9.10)
This way if an inflection point does occurs at t∗V , then t
∗
V = tc, where tc is the time at which R = 1. This
proves item (iii).
Furthermore, if V reaches a local minimum at t∗V , then V¨ (t
∗
V ) > 0 (instead of V¨ (t
∗
V ) = 0, as it is in
(9.7), which by (9.6) implies that
R(t∗V ) =
βp
cδ
U(t∗V ) > 1. (9.11)
This proves item (i).
On the other hand, if V reaches a local maximum at t∗V , then V¨ (t
∗
V ) < 0 (instead of V¨ (t
∗
V ) = 0, as it is
in (9.7), which by (9.6) implies that
R(t∗V ) =
βp
cδ
U(t∗V ) < 1. (9.12)
This proves item (ii). 
Figure 8 shows schematic plots of cases i, ii and iii of Theorem 9.1. For the sake of simplicity, β = δ =
p = c = 1, which means that Uc = 1, while the initial time is selected to be zero, i.e., t0 = 0.
Figure 8, first column, illustrates case (i), in whichRV (0) < 1 andR(0) < 1+α(0), beingα(0) = 0.43
(numerically computed). This simulation shows that even if R(0) > 1, but it is not greater than 1 + α(0),
the virus does not spread in the body host, i.e, it is strictly decreasing. Note that the maximum ofRV does
not reach 1. Figure 8, second column, illustrates case (ii), in which RV (0) < 1 and R(0) > 1 + α(0),
being α(0) = 0.43. This simulation shows that for R(0) > 1 + α(0), the maximum of RV is greater than
1, and the period of time in which RV > 1 is precisely the period of time the virus increases and reach
a maximum (i.e., it spreads in the body host). As expected, V reaches a minimum first, then I reaches a
maximum, then R reaches 1 (at tc) and, finally, V reaches a maximum, before to strictly decrease to zero.
Figure 8, third column, shows case(iii), in whichRV (0) > 1 andR(0) > 1 + α(0). As expected, the virus
spreads on the body host an it has only one global maximum.
Remark 7. The value of α is necessary to properly understand and characterize the system behavior
according to the initial conditions and parameters. Although it cannot be explicitly defined, it can be
computed numerically. Furthermore, it should be noted that for real patients data, this values use to be
small in comparison with R, given that β is small (see Table 2).
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